VYNE Therapeutics Inc

-0.01 (-1.58%)
Earnings Announcements

Vyne Therapeutics Reports Qtrly Loss Per Share 22 Cents

Published: 03/17/2022 13:37 GMT
VYNE Therapeutics Inc (VYNE) - Vyne Therapeutics Reports Year-end 2021 Financial Results and Provides Corporate Update.
Vyne Therapeutics - Expects Cash, Cash Equivalents & Restricted Cash As of Dec 31, 2021 & Proceeds From Sale Will Be Sufficient to Fund Operations Through Dec 31, 2022.
Vyne Therapeutics Inc - Qtrly Loss per Share $0.22.
Vyne Therapeutics Inc - Qtrly Adjusted Loss per Share $0.20.
Revenue is expected to be $0.1 Million
Adjusted EPS is expected to be -$0.17

Next Quarter Revenue Guidance is expected to be $0.1 Million
Next Quarter EPS Guidance is expected to be -$0.20

More details on our Analysts Page.